TECH Quote, Financials, Valuation and Earnings

Baxter International, Inc. has a net margin of 12.84% compared to Bio-Techne Corp.'s net margin of -34.8%. Bio-Techne Corp.'s return on equity of 4.06% beat Baxter International, Inc.'s return on equity of -12.97%.

Bio-Techne Corp. has a consensus price target of $75.25, signalling upside risk potential of 30.15%. On the other hand Baxter International, Inc. has an analysts' consensus of $21.63 which suggests that it could grow by 9.87%. Given that Bio-Techne Corp. has higher upside potential than Baxter International, Inc., analysts believe Bio-Techne Corp. is more attractive than Baxter International, Inc..

Bio-Techne Corp. has a beta of 1.479, which suggesting that the stock is 47.911% more volatile than S&P 500. In comparison Baxter International, Inc. has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.817%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.55%. Baxter International, Inc. offers a yield of 1.83% to investors and pays a quarterly dividend of $0.01 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Baxter International, Inc. pays out 180.98% of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

Bio-Techne Corp. quarterly revenues are $295.9M, which are smaller than Baxter International, Inc. quarterly revenues of $3B. Bio-Techne Corp.'s net income of $38M is higher than Baxter International, Inc.'s net income of -$1B. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 112.47x while Baxter International, Inc.'s PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.46x versus 0.90x for Baxter International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 12.84% compared to Bio-Techne Corp.'s net margin of 12.68%. Bio-Techne Corp.'s return on equity of 4.06% beat Boston Scientific Corp.'s return on equity of 12.55%.

Bio-Techne Corp. has a consensus price target of $75.25, signalling upside risk potential of 30.15%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 37.43%. Given that Boston Scientific Corp. has higher upside potential than Bio-Techne Corp., analysts believe Boston Scientific Corp. is more attractive than Bio-Techne Corp..

Bio-Techne Corp. has a beta of 1.479, which suggesting that the stock is 47.911% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.55%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $295.9M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Bio-Techne Corp.'s net income of $38M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 112.47x while Boston Scientific Corp.'s PE ratio is 39.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.46x versus 5.67x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 12.84% compared to Bio-Techne Corp.'s net margin of -121.83%. Bio-Techne Corp.'s return on equity of 4.06% beat Moderna, Inc.'s return on equity of -29.19%.

Bio-Techne Corp. has a consensus price target of $75.25, signalling upside risk potential of 30.15%. On the other hand Moderna, Inc. has an analysts' consensus of $42.25 which suggests that it could fall by -20.05%. Given that Bio-Techne Corp. has higher upside potential than Moderna, Inc., analysts believe Bio-Techne Corp. is more attractive than Moderna, Inc..

Bio-Techne Corp. has a beta of 1.479, which suggesting that the stock is 47.911% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.291, suggesting its more volatile than the S&P 500 by 29.087%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.55%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Bio-Techne Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $295.9M, which are smaller than Moderna, Inc. quarterly revenues of $678M. Bio-Techne Corp.'s net income of $38M is higher than Moderna, Inc.'s net income of -$826M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 112.47x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.46x versus 10.57x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revvity, Inc. has a net margin of 12.84% compared to Bio-Techne Corp.'s net margin of 12.41%. Bio-Techne Corp.'s return on equity of 4.06% beat Revvity, Inc.'s return on equity of 3.2%.

Bio-Techne Corp. has a consensus price target of $75.25, signalling upside risk potential of 30.15%. On the other hand Revvity, Inc. has an analysts' consensus of $119.56 which suggests that it could grow by 25.08%. Given that Bio-Techne Corp. has higher upside potential than Revvity, Inc., analysts believe Bio-Techne Corp. is more attractive than Revvity, Inc..

Bio-Techne Corp. has a beta of 1.479, which suggesting that the stock is 47.911% more volatile than S&P 500. In comparison Revvity, Inc. has a beta of 1.101, suggesting its more volatile than the S&P 500 by 10.105%.

Bio-Techne Corp. has a quarterly dividend of $0.08 per share corresponding to a yield of 0.55%. Revvity, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.07 per share. Bio-Techne Corp. pays 69.67% of its earnings as a dividend. Revvity, Inc. pays out 13.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Techne Corp. quarterly revenues are $295.9M, which are smaller than Revvity, Inc. quarterly revenues of $772.1M. Bio-Techne Corp.'s net income of $38M is lower than Revvity, Inc.'s net income of $95.8M. Notably, Bio-Techne Corp.'s price-to-earnings ratio is 112.47x while Revvity, Inc.'s PE ratio is 45.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Techne Corp. is 7.46x versus 3.90x for Revvity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.